Related Experiment Video
Updated: Dec 7, 2025

3D Printing of Preclinical X-ray Computed Tomographic Data Sets
Published on: March 22, 2013
Quality considerations on the pharmaceutical applications of fused deposition modeling 3D printing
Alice Melocchi1, Francesco Briatico-Vangosa2, Marco Uboldi3
1Sezione di Tecnologia e Legislazione Farmaceutiche "M. E. Sangalli", Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, via G. Colombo 71, 20133 Milano, Italy; Multiply Labs, 1760 Cesar Chavez Street Unit D, San Francisco, CA 94124, USA.
Abstract:
3D printing, and particularly fused deposition modeling (FDM), has rapidly brought the possibility of personalizing drug therapies to the forefront of pharmaceutical research and media attention. Applications for this technology, described in published articles, are expected to grow significantly in 2020. Where are we on this path, and what needs to be done to develop a FDM 2.0 process and make personalized medicines available to patients? Based on literature analysis, this manuscript aims to answer these questions and highlight the critical technical aspects of FDM as an emerging technology for manufacturing safe, high-quality personalized oral drug products. In this collaborative paper, experts from different fields contribute strategies for ensuring the quality of starting materials and discuss the design phase, printer hardware and software, the process, the environment and the resulting products, from the perspectives of both patients and operators.

